Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.55 |
| ▸ | HTR2A | P28223 | 5/20 | 0.55 |
| ▸ | HTR7 | P34969 | 5/20 | 0.55 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | HTR2C | P28335 | 3/20 | 0.55 |
| ▸ | DRD1 | P21728 | 2/20 | 0.55 |
| ▸ | HTR3A | P46098 | 2/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 2/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | NCF1 | P14598 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | HTR1D | P28221 | 1/20 | 0.54 |
| ▸ | HTR1B | P28222 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5187310 | 0.91 | HTR1A (0.60) | HTR1AHTR2AHTR7DRD2HTR2C | |
| SCHEMBL5366461 | 0.89 | HTR1A (0.62) | HTR1AHTR2AHTR7DRD2HTR2C | |
| SCHEMBL5187168 | 0.88 | HTR1A (0.62) | HTR1AHTR2AHTR7DRD2HTR2C | |
| SCHEMBL9283836 | 0.84 | DRD2 (0.59) | HTR1AHTR2AHTR7DRD2HTR2C | |
| SCHEMBL9287528 | 0.84 | HTR1A (0.55) | HTR1AHTR2AHTR7DRD2HTR2C | |
| SCHEMBL13711982 | 0.83 | DRD3 (0.60) | HTR1AHTR2AHTR7DRD2HTR2C | |
| Hydrochloric Acid SCHEMBL9639052 | 0.83 | DRD2 (0.57) | HTR1AHTR2AHTR7DRD2HTR2C | |
| SCHEMBL9643856 | 0.82 | HTR1A (0.74) | HTR1AHTR2AHTR7DRD2HTR2C | |
| SCHEMBL7592384 | 0.81 | HTR1A (0.60) | HTR1AHTR2AHTR7DRD2HTR2C | |
| SCHEMBL9229518 | 0.81 | HTR1A (0.60) | HTR1AHTR2AHTR7DRD2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196301-A1 | USE OF BINDING PARTNERS FOR 5-HT5 RECEPTORS FOR THE TREATMENT OF NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
| EP-1633735-B1 | DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES, PREPARATION METHODS THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI SA (FR) | 2011-11-30 | — | — | EP | disclosed |
| US-8034818-B2 | Therapeutic uses of derivatives of piperidinyl- and piperazinyl-alkyl carbamates | SANOFI-AVENTIS (FR) | 2011-10-11 | — | — | US | disclosed |
| EP-2266570-A1 | Use of binding partners for 5-HT5 receptors for treating neurodegenerative and neuropsychiatric disorders | Abbott GmbH & Co. KG (DE) | 2010-12-29 | — | — | EP | disclosed |
| CN-101239062-A | Use of 5-HT5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances | BASF AG (DE) | 2008-08-13 | — | — | CN | disclosed |
| CN-100370989-C | Use of 5-HT5 ligands for the manufacture of a medicament for the treatment of neurodegenerative disorders | BASF AG (DE) | 2008-02-27 | — | — | CN | disclosed |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | US | disclosed |
| US-7214798-B2 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-05-08 | — | — | US | disclosed |
| EP-1325917-B1 | Radiolabelled alkylamino-benzothiazole and -benzoxazole derivatives and their use as D4 ligands | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-03 | — | — | EP | disclosed |
| US-20060089344-A1 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2006-04-27 | — | — | US | disclosed |
| EP-1633735-A1 | DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES, PREPARATION METHODS THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004099176-A1 | DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES, PREPARATION METHODS THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2004-11-18 | — | — | WO | disclosed |
| US-20040202656-A1 | Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-10-14 | — | — | US | disclosed |
| EP-0912533-B1 | ALKYLAMINOBENZOTHIAZOLE AND -BENZOXAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2004-09-29 | — | — | EP | disclosed |
| US-6750221-B1 | IN VITRO BINDING STUDIES TO SCREEN COMPOUNDS FOR SELECTIVITY OF 5HT-5 OVER 5HT-1A RECEPTORS | BASF AKTIENGESELLSCHAFT (DE) | 2004-06-15 | — | — | US | disclosed |
| EP-1325917-A1 | Radiolabelled alkylamino-benzothiazole and -benzoxazole derivatives and their use as D4 ligands | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-07-09 | — | — | EP | disclosed |
| CN-1342080-A | Use of 5-HT 5 ligands for the treatment of neurodegenerative and neuropsychiatric disorders | BASF AG (DE) | 2002-03-27 | — | — | CN | disclosed |
| US-6224849-B1 | Alkylaminobenzothiazole and-benzoxazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-05-01 | — | — | US | disclosed |
| US-6103725-A | HIGH AFFINITY TO THE DOPAMINE D4 RECEPTOR; ANTAGONISTS; ANTIPSYCHOTIC AGENTS, E.G. SCHIZOPHRENIA, WITH REDUCED SIDE-EFFECTS; ANTIPSYCHOTIC AGENTS; ANXIOLYTIC AND ANTIEMETIC AGENTS; MOTORIC FUNCTIONS, ADDICTION, SLEEP, FEEDING | JANSSEN PHARMACEUTICA, N.V. (BE) | 2000-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089344-A1 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | CLCN2, CNR2, RCC2 | HTR1A 3455/4885HTR2A 2952/4885HTR7 2151/4885 |
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HTR1A 2958/4885HTR2A 2607/4885HTR7 1614/4885 |
| US-20040202656-A1 | Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders | HTR5A, GRM5, GRIK5 | HTR1A 8/4885HTR2A 17/4885HTR7 47/4885 |
| US-20120196301-A1 | USE OF BINDING PARTNERS FOR 5-HT5 RECEPTORS FOR THE TREATMENT OF NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS | HTR5A, GRM5, GRIK5 | HTR1A 8/4885HTR2A 17/4885HTR7 47/4885 |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3, H1-2 | HTR1A 2196/4885HTR2A 2056/4885HTR7 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.